Difference between revisions of "Chlorambucil (Leukeran)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
m |
||
| Line 30: | Line 30: | ||
*1957-03-18: Initial FDA approval | *1957-03-18: Initial FDA approval | ||
*2003-11-13 (oldest label available at Drugs @ FDA): indicated in the treatment of [[Chronic lymphocytic leukemia|chronic lymphatic (lymphocytic) leukemia]], [[:Category:Lymphomas|malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease]]. It is not curative in any of these disorders but may produce clinically useful palliation. ''(No supporting studies are cited)'' | *2003-11-13 (oldest label available at Drugs @ FDA): indicated in the treatment of [[Chronic lymphocytic leukemia|chronic lymphatic (lymphocytic) leukemia]], [[:Category:Lymphomas|malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease]]. It is not curative in any of these disorders but may produce clinically useful palliation. ''(No supporting studies are cited)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1956-09-14: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan | *'''Brand names:''' Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan | ||
| Line 57: | Line 58: | ||
[[Category:FDA approved in 1957]] | [[Category:FDA approved in 1957]] | ||
| + | [[Category:EMA approved in 1956]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 12:08, 13 June 2023
General information
Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established
Diseases for which it is used
- B-cell lymphoma of mucosa-associated lymphoid tissue
- Chronic lymphocytic leukemia
- Classical Hodgkin lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Waldenström macroglobulinemia
Diseases for which is was used
Patient drug information
- Chlorambucil (Leukeran) package insert[1]
- Chlorambucil (Leukeran) patient drug information (Chemocare)[3]
- Chlorambucil (Leukeran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1957-03-18: Initial FDA approval
- 2003-11-13 (oldest label available at Drugs @ FDA): indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. It is not curative in any of these disorders but may produce clinically useful palliation. (No supporting studies are cited)
History of changes in EMA indication
- 1956-09-14: EURD
Also known as
- Brand names: Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan
References
Categories:
- Drugs
- Oral medications
- Nitrogen mustards
- Alkylating agents
- Chronic lymphocytic leukemia medications
- Classical Hodgkin lymphoma medications
- Follicular lymphoma medications
- MALT lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Waldenström macroglobulinemia medications
- Breast cancer medications (historic)
- Ovarian cancer medications (historic)
- Testicular cancer medications (historic)
- FDA approved in 1957
- EMA approved in 1956
- WHO Essential Cancer Medicine